7,523 Shares in Edwards Lifesciences Co. (NYSE:EW) Bought by Callan Family Office LLC

Callan Family Office LLC acquired a new stake in Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 7,523 shares of the medical research company’s stock, valued at approximately $557,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $30,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $30,000. Prospera Private Wealth LLC bought a new stake in shares of Edwards Lifesciences during the third quarter worth $32,000. Avior Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at $46,000. Institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on EW shares. Truist Financial restated a “hold” rating and set a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Evercore ISI dropped their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Finally, Morgan Stanley raised their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $70.36 on Monday. The business has a 50-day simple moving average of $72.26 and a 200 day simple moving average of $70.39. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market capitalization of $41.37 billion, a price-to-earnings ratio of 10.10, a PEG ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares in the company, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 37,739 shares of company stock worth $2,799,104. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.